10 questions and answers about Iressa 13621079267 Do you understand Iressa purchasing and sales in India?

． Question: Which patients with lung cancer are suitable for treatment with Iressa? < ..
Answer: Iressa is mainly used to treat locally advanced or metastatic non-small cell lung cancer that has previously received or is not suitable for chemotherapy and radiotherapy.
． Question: Under what conditions is Iressa effective in treating lung cancer?
Answer: Current clinical research results show that Iressa is more effective in patients of Oriental race (mainly Asians), women, non-smokers, and patients with alveolar cell carcinoma or adenocarcinoma. But the main factors are not (Oriental race (mainly Asian), female, non-smoker), but the type of lung cancer and the patient's physical characteristics.
． Question: Iressa is highly effective against adenocarcinoma, but is it effective for patients with lung squamous cell carcinoma or other non-small cell lung cancer?
Answer: The efficacy of Iressa on lung squamous cell carcinoma is lower than that on adenocarcinoma and alveolar carcinoma. However, after choosing Iressa treatment according to the patient's actual situation, some patients with lung squamous cell carcinoma and other non-small cell lung cancer can still observe significant curative effects after taking Iressa.
. Question: A preliminary analysis of the international multi-center clinical trial of Iressa () in the United States at the end of last year showed that Iressa cannot prolong the survival of lung cancer patients, but why can Iressa still be officially used in China? Listed?
Answer: According to the information provided by AstraZeneca, the results of this clinical trial show that it cannot prolong the life of the overall patients. However, this trial also found that Iressa has an adverse effect on the survival of the Oriental people participating in the trial. The period has been extended by more than a month or longer. Currently, the longest patient has survived for years and is still in good health. The overall survival and remission rates in Eastern populations are significantly better than those in Western populations. This result once again confirmed the results of previous clinical studies suggesting that the effectiveness of Iressa treatment has unique advantages in patients of Oriental ethnicity. In clinical trials conducted in China, the effective rate of Iressa in treating advanced non-small cell lung cancer reached over %-%, and the clinical benefit rate reached over %. These trial results provide clinical supporting data for the marketing approval of Iressa in China.
． Question: Under what circumstances should Iressa be chosen for treatment, and under what circumstances should chemotherapy be chosen?
Answer: This is a question that often confuses patients. The current research results show that there is no significant difference in the effectiveness of simultaneous use of the two and monotherapy, so simultaneous use is not recommended. Iressa is currently approved as a second-line treatment for lung cancer. It is mainly used for advanced lung cancer after chemotherapy failure. It can also be used as a first-line drug for some patients who firmly refuse to accept chemotherapy or have contraindications to chemotherapy. However, the general recommendation is to consider chemotherapy first and then Iressa treatment. After Iressa treatment fails, systemic chemotherapy may still be considered if the patient has not received chemotherapy before and his physical condition permits. We have treated patients who were determined not to undergo chemotherapy, and their tumors shrank to partial remission or complete remission (complete remission) after taking Iressa. However, drug resistance and tumor progression occurred after several years of Iressa treatment, and the symptoms were still obvious after the patient was mobilized again for systemic chemotherapy. effective.
. Question: When does Iressa take effect and when should it be stopped?
Answer: Generally, the effect begins to take effect after about a week of oral administration. Therefore, the efficacy can be initially evaluated after taking it for a month. If it is effective, it should be continued for a long time until tumor progression occurs before discontinuation or adjustment is considered.
. Question: Can the dosage of Iressa be reduced after economic difficulties after effective treatment?
Answer: You should be very cautious when reducing or stopping the drug after the treatment is effective. We treated a patient who achieved complete tumor regression after Iressa treatment. After stopping the treatment due to economic reasons, the tumor recurred again, and Iressa treatment was restarted and the tumor completely regressed again. However, there are also cases where it is ineffective after stopping and then restarting the drug.
. Question: What are the side effects of Iressa? Can it be taken at home?
Answer: The most common side effects of Iressa are diarrhea and rash. Others include impaired liver function, nausea, vomiting, etc., but most of them are mild and can be relieved after symptomatic treatment. In addition, interstitial pneumonia occurs in a very small number of patients, requiring immediate hospitalization. It is recommended that the patient be hospitalized in the oncology department for observation during the initial period of taking the medicine. After the condition stabilizes, the patient can return home to take the medicine, but he should still go to the hospital for regular follow-up.
. Question: Is interstitial pneumonia caused by Iressa scary?
Answer: The global average incidence of interstitial pneumonia caused by Iressa is about %. The incidence in China is even lower, only .%. Fatal cases occasionally occur in Japan, but have not been reported in my country so far. We advocate that Iressa should be used with caution in individual patients with pulmonary fibrosis, extensive radiotherapy, and severely impaired lung function to prevent the occurrence of fatal interstitial pneumonia. However, a considerable number of patients with advanced lung cancer are complicated by other lung diseases (tuberculosis, emphysema, bronchial asthma, etc.), and the lungs are prone to infection. Therefore, it cannot be completely determined that all interstitial pneumonia is caused by Iressa. .
. Q: What are the prospects of molecular targeted therapy for lung cancer?
Answer: In recent years, the successive launch of new molecular targeted therapy drugs has changed the traditional treatment ideas and models, bringing new hope to patients with advanced lung cancer and their families. The combination of molecular targeted drugs and traditional treatment methods, or the combination of different molecular targeted drugs, is the future development direction.